Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufactured by: Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 U.S.A
Information about Lumakras (Sotorasib)
Lumakras is an oral medication specifically designed to target and inhibit the KRAS G12C mutation, which is associated with certain types of cancer, particularly non-small cell lung cancer (NSCLC).
Product Highlights
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that harbors the KRAS G12C mutation.
Key Ingredient
Sotorasib
Key Benefits
Provides a targeted treatment option for patients with KRAS G12C-mutated NSCLC.
May improve overall response rates and progression-free survival compared to traditional therapies.
Offers a convenient oral administration route, enhancing patient adherence.
Direction of Use
Take Lumakras exactly as prescribed by your healthcare provider.
The typical dosage is one tablet taken once daily, with or without food.
Consume the tablet whole; do not crush or chew it.
If you forget a dose, take it as soon as you recall, unless it's almost time for your next dose. Do not double up on doses.
Recommended LUMAKRAS Dose Reduction Levels for Side Effects
Dose Reduction Level
Dose
First dose reduction
480 mg (4 tablets) once daily
Second dose reduction
240 mg (2 tablets) once daily
Safety Concerns
Common side effects may include diarrhea, nausea, fatigue, and liver enzyme elevations.
Serious side effects can include hepatotoxicity and interstitial lung disease.
Regular monitoring of liver function and other laboratory tests may be required during treatment.
Avoid Lumakras (Sotorasib) If
You are allergic to sotorasib or any of its inactive ingredients.
You have severe liver impairment.
You are taking medications that may interact with sotorasib without consulting your healthcare provider.
You are pregnant or planning to become pregnant, as it may harm the fetus.
